Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cancer Research|January 15, 2011
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastasesBruce W Konicek, Jennifer R Stephens, Ann M McNulty, et al.Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.Cancer Research|April 23, 2009
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survivalJeremy R Graff, Bruce W Konicek, Rebecca L Lynch, et al.Molecular Cancer Therapeutics|December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activityRobert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy VolunteersNandita Bose, Nadine R Ottoson, Xiaohong Qiu, et al.Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.The Journal of Clinical Investigation|September 6, 2007
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJeremy R Graff, Bruce W Konicek, Thomas M Vincent, et al.Pageof 3